Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Rating of “Hold” by Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have earned an average rating of “Hold” from the fifteen research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $467.0833.

Several analysts have recently weighed in on MEDP shares. Barclays cut their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Royal Bank Of Canada cut their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Robert W. Baird cut their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, BMO Capital Markets cut their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th.

Insider Buying and Selling at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 20.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC lifted its holdings in shares of Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after purchasing an additional 324,293 shares during the last quarter. Wasatch Advisors LP lifted its holdings in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after purchasing an additional 38,760 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Performance

NASDAQ:MEDP opened at $527.07 on Friday. The stock has a market cap of $15.05 billion, a price-to-earnings ratio of 33.13, a PEG ratio of 2.67 and a beta of 1.18. The business has a fifty day moving average of $451.19 and a 200-day moving average of $497.02. Medpace has a 1 year low of $306.70 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company’s revenue was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts predict that Medpace will post 17.04 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.